Details
Stereochemistry | ACHIRAL |
Molecular Formula | C11H11ClN4O2 |
Molecular Weight | 266.684 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1CC(=O)N=C1NC(=O)NC2=CC(Cl)=CC=C2
InChI
InChIKey=DWPQODZAOSWNHB-UHFFFAOYSA-N
InChI=1S/C11H11ClN4O2/c1-16-6-9(17)14-10(16)15-11(18)13-8-4-2-3-7(12)5-8/h2-5H,6H2,1H3,(H2,13,14,15,17,18)
Molecular Formula | C11H11ClN4O2 |
Molecular Weight | 266.684 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/7042771Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/16040814 | https://www.ncbi.nlm.nih.gov/pubmed/19126569
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7042771
Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/16040814 | https://www.ncbi.nlm.nih.gov/pubmed/19126569
Fenobam is a selective and potent metabotropic glutamate (mGlu)5 receptor antagonist with inverse agonist activity. Fenobam was previously investigated as an anxiolytic in a number of phase II studies in the early 1980s. These studies revealed a mixed picture of anxiolytic efficacy, with double blind, placebo controlled trials variously reporting the compound as active or inactive. This discrepancy was not easily reconciled based on patient numbers, dose level, duration of treatment, or outcome measures. The positive effects seen in animal models of fragile X syndrome (FXS) treated with fenobam or other mGluR5 antagonists, the apparent lack of clinically significant adverse effects, and the potential beneficial clinical effects seen in this pilot trial support further study of the compound in adults with FXS.
CNS Activity
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16040814
Curator's Comment: 1978-1982
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL3227 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16040814 |
58.0 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7042771 Friedmann C, Davis L, Ciccone P, Rubin R. Phase II double-blind controlled study of a new anxiolytic, fenobam (McN-3377) vs placebo. Curr Ther Res 1980;27:144–51 Itil TM, Seaman BA, Huque M, Mukhopadhyay S, Blasucci D, Nq KT, Ciccone PE. The clinical and quantitative EEG effects and plasma levels of fenbam (McN-3377) in subjects with anxiety: an open rising dose tolerance and efficacy study. Curr Ther Res 1978;24:708–24 https://www.ncbi.nlm.nih.gov/pubmed/19126569 |
Primary | Unknown Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2.9 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31568235/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
FENOBAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
3.6 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31568235/ |
150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered: |
FENOBAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
1.4 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31568235/ |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
FENOBAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
167.4 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31568235/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
FENOBAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
183.6 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31568235/ |
150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered: |
FENOBAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
67.8 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31568235/ |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
FENOBAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
300 mg 1 times / day multiple, oral (max) Highest studied dose Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 29 Health Status: unhealthy Condition: anxiety Sex: M+F Food Status: UNKNOWN Population Size: 29 Sources: |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19126569
Twelve subjects, recruited from two fragile X clinics, received a single oral dose of 50-150 mg of fenobam.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24152913
Fenobam rarely exhibits cytotoxic effects in C6 cells at concentrations of 50-150 ng/ml. Fenobam (150 ng/ml) strongly enhanced the protective effect of PEP-1-FK506BP against H2O2-induced toxicity and DNA fragmentation in C6 cells.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:10:49 GMT 2023
by
admin
on
Fri Dec 15 16:10:49 GMT 2023
|
Record UNII |
078RCY7I27
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29756
Created by
admin on Fri Dec 15 16:10:49 GMT 2023 , Edited by admin on Fri Dec 15 16:10:49 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
4065
Created by
admin on Fri Dec 15 16:10:49 GMT 2023 , Edited by admin on Fri Dec 15 16:10:49 GMT 2023
|
PRIMARY | |||
|
135413554
Created by
admin on Fri Dec 15 16:10:49 GMT 2023 , Edited by admin on Fri Dec 15 16:10:49 GMT 2023
|
PRIMARY | |||
|
SUB07573MIG
Created by
admin on Fri Dec 15 16:10:49 GMT 2023 , Edited by admin on Fri Dec 15 16:10:49 GMT 2023
|
PRIMARY | |||
|
DTXSID5046770
Created by
admin on Fri Dec 15 16:10:49 GMT 2023 , Edited by admin on Fri Dec 15 16:10:49 GMT 2023
|
PRIMARY | |||
|
57653-26-6
Created by
admin on Fri Dec 15 16:10:49 GMT 2023 , Edited by admin on Fri Dec 15 16:10:49 GMT 2023
|
PRIMARY | |||
|
078RCY7I27
Created by
admin on Fri Dec 15 16:10:49 GMT 2023 , Edited by admin on Fri Dec 15 16:10:49 GMT 2023
|
PRIMARY | |||
|
C80667
Created by
admin on Fri Dec 15 16:10:49 GMT 2023 , Edited by admin on Fri Dec 15 16:10:49 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
SOLVATE->ANHYDROUS | |||
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |